News Updates

Sandoz announced it has received a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the use of its citrate-free high-concentration formulation of its biosimilar Hyrimoz, or adalimumab, for all indications, including diseases such as Crohn's disease, plaque psoriasis, rheumatoid arthritis ulcerative colitis and uveitis. The European Commission had previously approved Hyrimoz with a concentration of 50mg/mL in 2018 and gaining approval for the 100mg/mL HCF would provide patients with an option for reduced injection volume. PMLive (UK) (1/30)